#ADA25: Amgen plans more gradual MariTide dosing in Phase 3
Amgen intends to dose its long-acting obesity shot MariTide at a lower level in its Phase 3 than it did in Phase 2, after the drug’s side effects proved unmanageable in mid-stage research. The adverse ...
Amgen intends to dose its long-acting obesity shot MariTide at a lower level in its Phase 3 than it did in Phase 2, after the drug’s side effects proved unmanageable in mid-stage research.
The adverse ...
